MedTrace Logo

Circulating MicroRNAs in Understanding Pathogenesis of Systemic Lupus Erythematosis

NCT02756546 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2016-04-29

No results posted yet for this study

Summary

This study aims to identify the expression signature of miR-181a, miR-196a and miR-21 in plasma of SLE patients and difference in their expression among groups with different systemic lupus erythematosis disease activity index (SLEDAI) scores.

Conditions

  • Systemic Lupus Erythematosis

Interventions

DRUG

Cyclophosphamide

DRUG

Hydroxychloroquine

DRUG

Hydrocortisone

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2015-09-30
Completion
2015-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02756546 on ClinicalTrials.gov